Antiangiogenic drugs in ovarian cancer
- PMID: 19671017
- DOI: 10.1517/14656560903120907
Antiangiogenic drugs in ovarian cancer
Abstract
Background: There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer.
Objective: The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer.
Results/conclusion: Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.
Similar articles
-
Targeting angiogenesis in ovarian cancer.Cancer Treat Rev. 2012 Jun;38(4):272-83. doi: 10.1016/j.ctrv.2011.06.004. Epub 2011 Jul 18. Cancer Treat Rev. 2012. PMID: 21764518 Review.
-
Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.Trends Pharmacol Sci. 2008 Oct;29(10):515-9. doi: 10.1016/j.tips.2008.07.007. Epub 2008 Aug 28. Trends Pharmacol Sci. 2008. PMID: 18760845 Review.
-
Antiangiogenic therapy: a universal chemosensitization strategy for cancer?Science. 2006 May 26;312(5777):1171-5. doi: 10.1126/science.1125950. Science. 2006. PMID: 16728631
-
The interaction of radiation therapy and antiangiogenic therapy.Cancer J. 2008 Jul-Aug;14(4):207-13. doi: 10.1097/PPO.0b013e3181836af3. Cancer J. 2008. PMID: 18677126 Review.
-
Antiangiogenic therapies in breast cancer.Curr Opin Investig Drugs. 2009 Dec;10(12):1334-45. Curr Opin Investig Drugs. 2009. PMID: 19943205 Review.
Cited by
-
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
-
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Cancer Manag Res. 2011;3:25-38. doi: 10.2147/CMR.S8759. Epub 2010 Dec 30. Cancer Manag Res. 2011. PMID: 21734812 Free PMC article.
-
Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer.PLoS One. 2013;8(1):e54578. doi: 10.1371/journal.pone.0054578. Epub 2013 Jan 31. PLoS One. 2013. PMID: 23382918 Free PMC article.
-
Targeting Tumor Microenvironment by Metal Peroxide Nanoparticles in Cancer Therapy.Bioinorg Chem Appl. 2022 Dec 16;2022:5041399. doi: 10.1155/2022/5041399. eCollection 2022. Bioinorg Chem Appl. 2022. PMID: 36568636 Free PMC article. Review.
-
Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9. Oncogene. 2015. PMID: 24909162 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
